New drug combo may make bone marrow transplants safer for blood cancer patients
NCT ID NCT02996773
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested replacing the standard drug cyclophosphamide with bendamustine after a half-matched bone marrow transplant in 50 patients with various blood cancers. The goal was to see if this change could reduce side effects like graft-versus-host disease while still preventing transplant rejection. The study has completed both its Phase I and Phase Ib parts, focusing on safety and immune recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Bendamustine and cyclophosphamide
- What this could lead to
- If successful, this could lead to a safer way to prevent graft-versus-host disease after a half-matched bone marrow transplant, making this option more accessible for blood cancer patients.
- What could go wrong
- This is an early-phase trial with only 50 participants, so results are preliminary. The substitution may not work as well as standard treatment, and risks like graft failure or infection remain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Arizona Cancer Center
Tucson, Arizona, 85724, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas